Gennaro Nuzzo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gennaro Nuzzo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Felice Giuliante
Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
14 shared publications Maria Vellone
6 shared publications- Francesco Ardito
Hepatobiliary Surgery Unit, Foundation Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy
5 shared publications - Agostino Maria De Rose
Hepatobiliary Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, L.go A. Gemelli 8, 00168 Rome, Italy
4 shared publications Ivo Giovannini
Hepatobiliary Surgery Unit, Department of Surgical Sciences, Catholic University School of Medicine, Rome, Italy
4 shared publications- Ivo Giovannini
Department of Surgical Sciences, Hepatobiliary Unit, Catholic University School of Medicine, Rome, Italy
4 shared publications
Latest Publications
- 1 January 2015
- Published by Springer Nature
- p. 111-127
Cystic Bile Duct Dilatations and Caroli’s Disease
- 1 January 2015
- Published by Springer Nature
- p. 111-127
Cystic Bile Duct Dilatations and Caroli’s Disease
- 1 January 2015
- Published by Springer Nature
- p. 129-146
Hepatolithiasis
- 22 August 2014
- Published by Springer Nature in Updates in Surgery
- Vol. 66 (3) , 169-170
The memory of a friend: Lorenzo Capussotti (1947–2014)
- 22 August 2014
- Published by Springer Nature in Updates in Surgery
- Vol. 66 (3) , 169-170
The memory of a friend: Lorenzo Capussotti (1947–2014)
- Open Access
- 1 January 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (2) , 419
Impairment of hepatocellular excretory function, sepsis and liver insufficiency after liver resection
- 1 January 2014
- Published by Springer Nature in Critical Care
- Vol. 18 (2) , 419
Open AccessImpairment of hepatocellular excretory function, sepsis and liver insufficiency after liver resection
- 1 May 2013
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 60 (123) , 557-62
Liver resection for gastric cancer metastases.
Surgical indications in patients with liver metastases from gastric cancer are debated. To analyze outcomes of surgery and the impact of neoadjuvant chemotherapy (NeoCTx). Consecutive patients undergoing liver resection for gastric metastases between January 1997 and December 2008 were analyzed. Liver metastases were synchronous in 9 patients and multiple in 5. Eight patients received NeoCTx. NeoCTx and non-NeoCTx groups had similar characteristics. Mortality was nil, morbidity was 40%. After a mean follow-up of 42.5 months, 5-year survival rate was 33.2%. Presence of multiple metastases was a negative prognostic factor (p=0.029), while synchronous presentation and NeoCTx were not. Disease-free survival rates were significantly different by stratifying patients according to response to chemotherapy: at 5 years 32.4% in non-NeoCTx group, 0% in disease progression (PD) while on NeoCTx group and 60.0% in non-PD while on NeoCTx group (p=0.018). One-year recurrence rates were 40%, 100% and 0%, (p=0.020). Liver resection for gastric metastases achieves good long-term results, especially in solitary metastases. NeoCTx helps to select candidates for surgery and, in patients without PD, is associated with improved disease-free survival
- 1 May 2013
- Published by Update Medical Publishing in Hepatogastroenterology
- Vol. 60 (123) , 557-62
Liver resection for gastric cancer metastases.
Surgical indications in patients with liver metastases from gastric cancer are debated. To analyze outcomes of surgery and the impact of neoadjuvant chemotherapy (NeoCTx). Consecutive patients undergoing liver resection for gastric metastases between January 1997 and December 2008 were analyzed. Liver metastases were synchronous in 9 patients and multiple in 5. Eight patients received NeoCTx. NeoCTx and non-NeoCTx groups had similar characteristics. Mortality was nil, morbidity was 40%. After a mean follow-up of 42.5 months, 5-year survival rate was 33.2%. Presence of multiple metastases was a negative prognostic factor (p=0.029), while synchronous presentation and NeoCTx were not. Disease-free survival rates were significantly different by stratifying patients according to response to chemotherapy: at 5 years 32.4% in non-NeoCTx group, 0% in disease progression (PD) while on NeoCTx group and 60.0% in non-PD while on NeoCTx group (p=0.018). One-year recurrence rates were 40%, 100% and 0%, (p=0.020). Liver resection for gastric metastases achieves good long-term results, especially in solitary metastases. NeoCTx helps to select candidates for surgery and, in patients without PD, is associated with improved disease-free survival
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (TACE-RFA) for Treatment of Intermediate Hepatocellular Carcinoma
- 1 May 2013
- Published by Elsevier in Gastroenterology
- Vol. 144 (5)
Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (TACE-RFA) for Treatment of Intermediate Hepatocellular Carcinoma
- 7 September 2010
- Published by Springer Nature in Updates in Surgery
- Vol. 62 (3-4) , 131-133
Plasma cholesterol level after hepatopancreatobiliary surgery provides information on the postoperative clinical course
- 7 September 2010
- Published by Springer Nature in Updates in Surgery
- Vol. 62 (3-4) , 131-133
Plasma cholesterol level after hepatopancreatobiliary surgery provides information on the postoperative clinical course
- 17 July 2010
- Published by Springer Nature in Updates in Surgery
- Vol. 62 (1) , 11-19
Intrahepatic cholangiocarcinoma: prognostic factors after liver resection
Liver resection may represent the only hope of cure for patients with intrahepatic cholangiocarcinoma (IHC) but long-term results are still far from satisfactory and the impact of prognostic factors is still controversial. Fifty-five patients underwent hepatectomy for IHC between 1997 and 2008 in our unit. Features of the patients and the tumors, operations, postoperative and long-term results were retrospectively assessed. Twenty-one patients had HBV/HCV infection, four had congenital biliary dilatation. Thirty-two patients had increased CA 19-9; 12 had multiple (≥4) tumors. Operations included 43 major resections, with 9 resections of biliary confluence, 40 regional lymphadenectomies. Operative mortality and morbidity were 0 and 27.3%, respectively. There were 44 R0-resections (80.0%). Lymphadenectomy yielded lymph node metastases in 14 cases (14/40; 35.0%). Five-year overall and disease-free survival rates were 30.2 and 27.5%, respectively. At multivariate analysis the strongest poor prognostic factor for overall survival was tumor stage. This factor, with multiplicity of lesions (≥4) and tumor grading > 2, was significant predictor of recurrence. CA19-9 > 100 IU/mL and tumor grading > 2 were found to be significantly related with early multinodular hepatic recurrence. Patients with lymph node metastases had significantly lower overall and disease-free survival but patients who underwent lymph node dissection with negative lymph nodes at final pathology showed significantly higher 5-year disease-free survival than patients who did not underwent lymphadenectomy. In conclusion, these results support the role of hepatectomy with regional lymphadenectomy as the best available treatment for IHC. Prognosis after liver resection correlates with clinical stage and multiplicity of lesions.
- 17 July 2010
- Published by Springer Nature in Updates in Surgery
- Vol. 62 (1) , 11-19
Intrahepatic cholangiocarcinoma: prognostic factors after liver resection
Liver resection may represent the only hope of cure for patients with intrahepatic cholangiocarcinoma (IHC) but long-term results are still far from satisfactory and the impact of prognostic factors is still controversial. Fifty-five patients underwent hepatectomy for IHC between 1997 and 2008 in our unit. Features of the patients and the tumors, operations, postoperative and long-term results were retrospectively assessed. Twenty-one patients had HBV/HCV infection, four had congenital biliary dilatation. Thirty-two patients had increased CA 19-9; 12 had multiple (≥4) tumors. Operations included 43 major resections, with 9 resections of biliary confluence, 40 regional lymphadenectomies. Operative mortality and morbidity were 0 and 27.3%, respectively. There were 44 R0-resections (80.0%). Lymphadenectomy yielded lymph node metastases in 14 cases (14/40; 35.0%). Five-year overall and disease-free survival rates were 30.2 and 27.5%, respectively. At multivariate analysis the strongest poor prognostic factor for overall survival was tumor stage. This factor, with multiplicity of lesions (≥4) and tumor grading > 2, was significant predictor of recurrence. CA19-9 > 100 IU/mL and tumor grading > 2 were found to be significantly related with early multinodular hepatic recurrence. Patients with lymph node metastases had significantly lower overall and disease-free survival but patients who underwent lymph node dissection with negative lymph nodes at final pathology showed significantly higher 5-year disease-free survival than patients who did not underwent lymphadenectomy. In conclusion, these results support the role of hepatectomy with regional lymphadenectomy as the best available treatment for IHC. Prognosis after liver resection correlates with clinical stage and multiplicity of lesions.